There's no question that glucagon-like peptide 1 (GLP-1) agonists represent a major advance in the treatment of obesity for patients with or without diabetes. In clinical trials, participants lost 15%-20% of their body weight, depending on the drug.
But studies also have shown that once people stop taking these drugs — either by choice, because of shortage, or lack of access — they regain most, if not all, the weight they lost.
Arguably more frustrating is the fact that those who continue on the drug eventually reach a plateau, at which point, the body seemingly stubbornly refuses to lose more weight. Essentially, it stabilizes at its set point, said Fatima Cody Stanford, MD, MPH, MPA, MBA, an obesity medicine physician at Massachusetts General Hospital and associate professor at Harvard Medical School in Boston.
Medscape
Me: Conclusion - Obesity Weight Reduction does not work long term, so why do it at all?
They made me start to go blind, until I stopped taking them - then my eyesight returned fine, heard elsewhere they can give you Heart Attacks, but that might have been from the ModRNA vaccines (made in a Laboratory) which they told you were mRNA (naturally occurring) - no, another lie